delivering-therapies
Delivering therapies
Toggle navigation
Toggle navigation
English
中文
Home
Our Company
Our approach
Board of directors
Management team
Company history
Developing science
Live biotherapeutics
Microbiome
MicroRx
MicroDx
Pipeline
Intellectual property
Delivering therapies
Clinical development
Manufacturing
Regulatory
Clinical
Clinical trials
For patients
For clinicians
Newsroom
Press releases
Events
Posters and publications
Video and audio
Investors
Reports and presentations
Shareholder information
Corporate governance
QCA code compliance
Share price information
Regulatory News
Financial calendar
AIM Rule 26
4d
Our Company
Our approach
Board of directors
Management team
Company history
developing-science
Developing science
Live biotherapeutics
Microbiome
MicroRx
MicroDx
Pipeline
Intellectual property
delivering-therapies
Delivering therapies
Clinical development
Manufacturing
Regulatory
clinical-trials
Clinical
Clinical trials
For patients
For clinicians
Newsroom
Press releases
Events
Posters and publications
Video and audio
investors
Investors
Reports and presentations
Shareholder information
Corporate governance
QCA code compliance
Share price information
Regulatory News
Financial calendar
AIM Rule 26
Home
Contact
Join us
LinkedIn
Clinical development
The intrinsic safety of live biotherapeutics means that we can get them to the patients that need them faster
manufacturing
Manufacturing
We have an end-to-end manufacturing capability to accelerate our candidates through clinical development
regulatory
Regulatory
Live biotherapeutics are a recognised and regulated new class of medicines
BACK TO TOP